Olon SpA, a manufacturer of active pharmaceutical ingredients (APIs) and subsidiary of the Milan, Italy-based P&R Group, a chemical/pharmaceutical company, has agreed to acquire INFA Group, an API and fine chemicals manufacturer headquartered in Milan, Italy.

Olon has five manufacturing sites in northern Italy (Rodano, Settimo Torinese, Garbagnate Milanese, Mulazzano and Dorno) with more than 800 employees. INFA Group, with more than 400 employees, has two manufacturing sites in Italy (Labochim and Sifavitor) and one in Spain (Derivados Químicos).

The move further strengthens Olon’s position in providing generic APIs by more than doubling Olon’s generic drug portfolio to more than 200 products and also further strengthens its position in contract development and manufacturing services. A combined Olon and Infa will have about 130 active US drug master files and more than 50 European Union certificates of suitability or compliance with the European Pharmacopoeia and have eight manufacturing facilities self-identified under the Generic Drug User Fee Amendments Act (GDUFA).

Olon is one of four companies of the P&R Group, which further includes SIR Industrial (industrial chemicals), Fidia Farmaceutic (finished dosage forms) and Biofarmitalia (patches and devices). P&R Group has 2000 employees with 2015 sales of more than EUR 550 million ($616 million).

Olon had 2015 revenues of more than EUR 200 million ($224 million). The 2016 total pro-forma revenue of a combined company Olon and Infa is projected at more than EUR 300 million ($336 million).

Source: INFA Group